Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
तुलना करने के लिए मीट्रिक्स | PALI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPALIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −22.4x | −2.8x | −0.5x | |
PEG अनुपात | −0.27 | −0.10 | 0.00 | |
क़ीमत/बुक | 78.4x | 4.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 64.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 343.8% | 56.7% | 50.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | −3.6% | 8.6% | अनलॉक करें |